Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12735158 | 0.86 | TRPA1 (0.39) | CACNA1BBLMPMP22HSD17B10 | |
| SCHEMBL10170320 | 0.85 | BLM (0.48) | CACNA1BKCNQ3KCNQ2BLMPMP22 | |
| SCHEMBL19546089 | 0.82 | BLM (0.41) | CACNA1BBLMPMP22HSD17B10 | |
| SCHEMBL15696992 | 0.81 | PIK3CD (0.34) | — | |
| SCHEMBL18053151 | 0.78 | KDM4E (0.39) | BLMPMP22HSD17B10 | |
| SCHEMBL18412665 | 0.78 | BLM (0.55) | BLMPMP22HSD17B10 | |
| SCHEMBL21427999 | 0.78 | CYP2D6 (0.37) | CACNA1BBLMPMP22HSD17B10 | |
| SCHEMBL18412664 | 0.78 | BLM (0.36) | BLMPMP22HSD17B10 | |
| SCHEMBL10247121 | 0.78 | CA12 (0.37) | — | |
| SCHEMBL10170635 | 0.78 | ALOX15 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-02-09 | — | — | US | disclosed |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | CACNA1B 1955/4885KCNQ3 1217/4885KCNQ2 1363/4885 |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | CACNA1B 1955/4885KCNQ3 1217/4885KCNQ2 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.